drugset / Trial / NCT02614404

Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria

NCT02614404

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the efficacy and safety of imatinib in combination with dihydroartemisinin plus piperaquine in the treatment uncomplicated P. falciparum malaria in adult male patients.

Timeline

Start
2015-11
Primary completion
2016-12-02
Completion
2017-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule 400 mg
Background ARTENIMOL Small molecule 40 mg
Background piperaquine Small molecule 320 mg